ICAD Inc
NASDAQ:ICAD

Watchlist Manager
ICAD Inc Logo
ICAD Inc
NASDAQ:ICAD
Watchlist
Price: 1.72 USD 2.08%
Market Cap: 45.6m USD
Have any thoughts about
ICAD Inc?
Write Note

ICAD Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ICAD Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
ICAD Inc
NASDAQ:ICAD
Other Long-Term Assets
$627k
CAGR 3-Years
119%
CAGR 5-Years
66%
CAGR 10-Years
15%
Veeva Systems Inc
NYSE:VEEV
Other Long-Term Assets
$401.3m
CAGR 3-Years
84%
CAGR 5-Years
52%
CAGR 10-Years
59%
Inspire Medical Systems Inc
NYSE:INSP
Other Long-Term Assets
$11m
CAGR 3-Years
280%
CAGR 5-Years
94%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Other Long-Term Assets
$46.5m
CAGR 3-Years
112%
CAGR 5-Years
102%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Other Long-Term Assets
$104.8m
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
16%
W
Waystar Holding Corp
NASDAQ:WAY
Other Long-Term Assets
$72.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ICAD Inc
Glance View

Market Cap
45.3m USD
Industry
Health Care

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

ICAD Intrinsic Value
1.67 USD
Overvaluation 3%
Intrinsic Value
Price

See Also

What is ICAD Inc's Other Long-Term Assets?
Other Long-Term Assets
627k USD

Based on the financial report for Sep 30, 2024, ICAD Inc's Other Long-Term Assets amounts to 627k USD.

What is ICAD Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
15%

Over the last year, the Other Long-Term Assets growth was -80%. The average annual Other Long-Term Assets growth rates for ICAD Inc have been 119% over the past three years , 66% over the past five years , and 15% over the past ten years .

Back to Top